Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial by Giralt, Jordi et al.
www.thelancet.com/oncology   Published online January 15, 2015   http://dx.doi.org/10.1016/S1470-2045(14)71200-8 1
Articles
Panitumumab plus radiotherapy versus chemoradiotherapy 
in patients with unresected, locally advanced squamous-cell 
carcinoma of the head and neck (CONCERT-2): a randomised, 
controlled, open-label phase 2 trial
Jordi Giralt, Jose Trigo, Sandra Nuyts, Mahmut Ozsahin, Krzysztof Skladowski, Georges Hatoum, Jean-Francois Daisne, 
Alejandro César Yunes Ancona, Anthony Cmelak, Ricard Mesía, Alicia Zhang, Kelly S Oliner, Ari VanderWalde
Summary
Background We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus 
radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the 
head and neck.
Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally 
advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 
18 years and older with stage III, IVa, or IVb, previously untreated, measurable (≥10 mm for at least one dimension), 
locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative 
Oncology Group performance status of 0–1 were randomly assigned (2:3) by an independent vendor to open-label 
chemoradiotherapy (two cycles of cisplatin 100 mg/m² during radiotherapy) or to radiotherapy plus panitumumab 
(three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratiﬁ ed randomisation 
with a block size of ﬁ ve. All patients received 70–72 Gy to gross tumour and 54 Gy to areas of subclinical disease with 
accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all 
randomly assigned patients who received at least one dose of their assigned protocol-speciﬁ c treatment (chemotherapy, 
radiation, or panitumumab). The trial is closed and this is the ﬁ nal analysis. This study is registered with ClinicalTrials.
gov, number NCT00547157.
Findings Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in 
the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 
2 years was 61% (95% CI 47–72) in the chemoradiotherapy group and 51% (40–62) in the radiotherapy plus 
panitumumab group. The most frequent grade 3–4 adverse events were mucosal inﬂ ammation (25 [40%] of 
62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab 
group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse 
events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in 
the radiotherapy plus panitumumab group.
Interpretation Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected 
stage III–IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced 
squamous-cell carcinoma of the head and neck needs to be reassessed.
Funding Amgen.
Introduction
Monoclonal antibodies against EGFR have shown 
eﬃ  cacy in both metastatic and locally advanced head and 
neck cancer.1,2 In the locally advanced setting, Bonner 
and colleagues2,3 reported that the anti-EGFR antibody 
cetuximab in combination with radiotherapy is more 
eﬀ ective than radiotherapy alone.
Radiotherapy alone is no longer the standard of care for 
patients with locally advanced disease with the proven 
eﬃ  cacy of cisplatin-based chemoradiotherapy.4 Although 
the addition of anti-EGFR antibodies to cisplatin-based 
chemoradiotherapy has not been shown to have a 
signiﬁ cant advantage over chemoradiotherapy alone,5,6 
no studies formally testing the substitution of cisplatin 
with an anti-EGFR antibody in a randomised trial have 
yet been reported.
Panitumumab (Vectibix, Amgen, Thousand Oaks, CA, 
USA), a fully human monoclonal anti-EGFR antibody, 
has shown a progression-free survival advantage in 
patients with metastatic squamous-cell carcinoma of the 
head and neck, although without a signiﬁ cant overall 
survival beneﬁ t,7 and has been shown to have an 
enhanced eﬀ ect in combination with radiation in the 
preclinical setting.8
The CONCERT trials (CONcomitant Chemotherapy 
and/or EGFR inhibition with Radiation Therapy) are two 
Lancet Oncol 2015
Published Online
January 15, 2015
http://dx.doi.org/10.1016/
S1470-2045(14)71200-8
See Online/Comment
http://dx.doi.org/10.1016/
S1470-2045(15)70006-9
See Online/Articles
http://dx.doi.org/10.1016/
S1470-2045(14)71198-2
Hospital Vall d’Hebron, 
Barcelona, Spain 
(Prof J Giralt MD); Universitat 
Autònoma de Barcelona, 
Bellaterra, Spain (Prof J Giralt); 
Hospital Virgen de la Victoria, 
Málaga, Spain (J Trigo MD); 
University Hospital 
Gasthuisberg, Leuven, Belgium 
(Prof S Nuyts MD); Centre 
Hospitalier Universitaire 
Vaudois, Lausanne, 
Switzerland (M Ozsahin MD); 
Centrum Onkologii Instytut M. 
Sklodowskiej-Curie, Gliwice, 
Poland (K Skladowski MD); 
University of Miami, Sylvester 
Comprehensive Cancer Center, 
Miami, FL, USA (G Hatoum MD); 
Clinique Sainte Elisabeth, 
Namur, Belgium 
(J-F Daisne MD); Unidad de 
Oncología Servicios de Salud 
del Estado de Puebla, Puebla, 
Mexico (A C Yunes Ancona MD); 
Vanderbilt University Medical 
Center, Nashville, TN, USA 
(Prof A Cmelak MD); Institut 
Catala d’Oncologia (ICO) – 
L’Hospitalet, Barcelona, Spain 
(Prof R Mesía MD); and 
Amgen, Thousand Oaks, CA, 
USA (A Zhang PhD, 
K S Oliner PhD, 
A VanderWalde MD)
Correspondence to:
Prof Jordi Giralt, Radiation 
Oncology Department, Vall 
d’Hebron University Hospital, 
Vall d’Hebron Institute of 
Oncology, P Vall d’Hebron 
119–129, 08035 Barcelona, Spain
jgiralt@vhebron.net
Articles
2 www.thelancet.com/oncology   Published online January 15, 2015   http://dx.doi.org/10.1016/S1470-2045(14)71200-8
international, randomised, controlled, phase 2 trials 
designed to explore panitumumab as an adjunct to, or 
substitute for, cisplatin-based chemotherapy in 
combination with radiotherapy for the treatment of 
locally advanced squamous-cell carcinoma of the head 
and neck. Eligibility criteria, randomisation factors, and 
patient assessments were identical between the two 
trials; the studies enrolled patients during the same time 
period.
The CONCERT-2 trial, reported here, investigated the 
eﬀ ect of the substitution of cisplatin with panitumumab, 
testing the combination of panitumumab with 
accelerated fractionation radiotherapy compared with 
cisplatin-based chemoradiotherapy using accelerated 
fractionation as ﬁ rst-line treatment of locally advanced 
squamous-cell carcinoma of the head and neck. In a 
preplanned analysis, we also assessed treatment eﬀ ect by 
human papillomavirus (HPV) status.
Methods
Study design and patients
In this international, open-label, randomised, controlled, 
phase 2 trial, we recruited patients with locally advanced 
squamous-cell carcinoma of the head and neck from 
sites in eight countries worldwide.
Selected eligibility criteria included stage III or IVa–b 
(M0) histologically or cytologically conﬁ rmed squamous-
cell carcinoma of the oral cavity, oropharynx, hypopharynx, 
or larynx (patients with nasopharygeal carcinomas were 
ineligible); Eastern Cooperative Oncology Group 
performance status of 0–1; bidimensionally measurable 
disease with at least one dimension of 10 mm or longer; 
age 18 years or older; eligible laboratory readings 10 days 
or fewer before randomisation (ie, absolute neutrophil 
count ≥1·5 × 10⁹ cells per L; platelet count ≥100 × 10⁹ cells 
per L; haemoglobin ≥90 g/L; creatinine clearance 
≥0·84 mL/s per m² calculated from a 24 h urine collection, 
required for patients with a serum creatinine concen-
tration that was greater than the upper limit of normal 
[ULN], or by the Cockcroft-Gault method; aspartate 
aminotransferase ≤2 × ULN; alanine aminotransferase 
≤2 × ULN; total bilirubin ≤2 × ULN; and serum 
magnesium greater than or equal to the lower limit of 
normal); no previous surgery for squamous-cell 
carcinoma of the head and neck; no previous radiation 
therapy in the planned ﬁ eld; no previous anti-EGFR 
therapy; and no previous systemic chemotherapy for 
squamous-cell carcinoma of the head and neck. See the 
appendix for a complete list of all inclusion and exclusion 
criteria.
The study protocol was approved by independent ethics 
committees at participating centres; all patients provided 
signed informed consent.
Randomisation and masking
Patients were randomly assigned in a 2:3 ratio to 
accelerated fractionation radiotherapy and cisplatin or to 
accelerated fractionation radiotherapy and panitumumab, 
in a block size of ten (appendix). An independent 
randomisation group within the trial funder (Amgen) that 
did not participate in any clinical trial activities generated 
the randomisation sequence. We chose a 2:3 
randomisation ratio to increase exposure to panitumumab 
in the radiotherapy plus panitumumab group.9 Central 
randomisation was stratiﬁ ed by site of primary tumour 
(hypopharynx or oral cavity vs oropharynx or larynx), 
radiotherapy delivery modality (intensity-modulated radio-
therapy vs three-dimensional [3D]-conformal radiation 
therapy), nodal status (N0 vs N+), and tumour classiﬁ cation 
(T1–3 vs T4). On the basis of stratiﬁ cation variables entered 
into the randomisation system, the patient was assigned 
the next available randomisation record from the assigned 
stratum. Research sites enrolled patients by calling an 
independent vendor that assigned patients to treatment 
groups. Since this trial was open-label, both trial patients 
and members of the study team at the research sites knew 
to which treatment group a patient was assigned; however, 
the trial funder biostatistics and programming groups 
were masked to assigned treatment until the database was 
locked for the ﬁ nal analysis.
Procedures
Radiation target volumes were deﬁ ned by radiological 
ﬁ ndings, as in the CONCERT-1 trial.6 Two intensity-
modulated radiotherapy techniques could be used in this 
trial: a concomitant boost technique or a simultaneous 
integrated boost technique. The radiotherapy total dose 
of 70–72 Gy was administered in both groups in 
30–32 fractions, in one to two fractions per day according 
to the technique used, for about 5 days per week for 
6–6·5 weeks to planning target volume 1 (PTV1). Areas at 
risk for subclinical disease were expanded by 0·5 cm to 
planning target volume 2 according to published 
guidelines and received 54 Gy at 1·64–1·80 Gy daily 
fractions (depending on the technique of radiotherapy 
administration). Planned modality (intensity-modulated 
radiotherapy or 3D-conformal radiation therapy) was 
declared before randomisation. For sites using intensity-
modulated radiotherapy, accreditation was required. Plan 
normalisation provided 95% coverage of the planning 
target volume (PTV) within the prescribed dose. The 
spinal cord dose was 45 Gy or less, with no more than 1% 
to receive up to 50 Gy.
For patients randomly assigned to the chemo-
radiotherapy group, cisplatin was administered at a dose 
of 100 mg/m² on days 1 and 22 of radiotherapy (plus or 
minus 3 days). For patients randomly assigned to the 
radiotherapy plus panitumumab group, panitumumab 
was administered as a 60 min (plus or minus 15 min) 
intravenous infusion at a dose of 9·0 mg/kg given every 
3 weeks in three doses on days 1, 22, and 43 of 
radiotherapy (plus or minus 3 days).
Panitumumab was withheld for grade 4 toxicities that 
occurred within the radiation ﬁ eld (eg, radiation 
See Online for appendix
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dermatitis and mucositis or stomatitis) and if a delay in 
more than 5 (cumulative) planned days of radiotherapy 
occurred since the previous dose of panitumumab; a 
planned day of radiotherapy did not include weekends, 
holidays, or breaks for any reason other than toxicity. Any 
planned panitumumab dose that occurred during a 
radiotherapy treatment break was delayed until 
radiotherapy resumed.
Panitumumab dosing was also withheld for any 
symptomatic skin-related or nail-related toxicity that 
needed to be treated with narcotics, systemic steroids, or 
that the patient felt to be intolerable, or for a skin or nail 
infection that needed to be treated with intravenous 
antibiotics or intravenous antifungal treatments, or if 
surgical debridement was needed, or for any skin-related 
or nail-related serious adverse event.
Additionally, panitumumab dosing was withheld for 
any grade 3 or 4 toxicity with the exception of hypo-
magnesaemia or hypocalcaemia that persisted despite 
aggressive magnesium or calcium replacement, grade 3 
or 4 nausea or vomiting that persisted despite maximum 
supportive care, and grade 3 or worse anaemia or grade 4 
thrombocytopenia that could not be managed by one or 
more transfusions.
Panitumumab dose reductions to 80% of the starting 
dose (7·2 mg/kg for the ﬁ rst dose reduction) and 60% of 
the starting dose (5·4 mg/kg for the second dose 
reduction) were required when beginning re-treatment.
For in-ﬁ eld toxicities (eg, radiation dermatitis and 
stomatitis), once radiotherapy was completed, any 
panitumumab dose that was still planned could be 
administered only after in-ﬁ eld toxicity had resolved 
from grade 4 to grade 2 or better. Patients who had a 
grade 4 in-ﬁ eld toxicity during the radiotherapy treatment 
phase did not receive any additional panitumumab 
during the radiotherapy course.
Patients who had a delay in more than 5 (cumulative) 
planned days of radiotherapy since the previous dose of 
panitumumab did not receive any additional 
panitumumab during the radiotherapy course. Once 
radiotherapy was completed, any panitumumab dose 
that was still planned could be administered (unless the 
patient had any other toxicities that met the requirement 
to withhold panitumumab).
For skin-related or nail-related toxicities (outside of the 
radiotherapy ﬁ eld), panitumumab administration could 
be restarted once the patient recovered to the point at 
which the patient felt that the symptomatic skin-related 
or nail-related toxicity was tolerable; or when systemic 
steroids were no longer needed; or when intravenous 
antibiotics or intravenous antifungal treatments were no 
longer needed; or when the adverse event had improved 
to grade 2 or better or returned to baseline.
For non-skin-related or non-nail-related toxicities 
(outside of the radiotherapy ﬁ eld), panitumumab 
administration could be restarted once the adverse event 
improved to grade 1 or better or returned to baseline.
Radiological assessments (CT scan of the head, neck, 
and chest [MRI allowed]) were done according to a 
modiﬁ cation of the WHO criteria by central review. 
Intravenous contrast could be used in patients who did 
not have a contraindication to it, and PET scans were 
fused with the CT scan with image registration techniques 
at the investigator’s discretion for target volume 
delineation. After completion of radiotherapy, patients 
were assessed clinically at 30 days (plus or minus 7 days) 
and clinically and radiographically at 60 days (plus or 
minus 7 days) for disease status. Therapeutic neck 
dissection was required for patients with persistent or 
residual nodal disease at the 60 day assessment. Additional 
radiographical and clinical tumour assessments were 
done at 6 months (plus or minus 2 weeks) and 12, 18, and 
24 months (plus or minus 1 month) from randomisation, 
and then every 6 months (plus or minus 3 months) 
thereafter until disease progression or end of study. 
Adverse events were graded using the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTCAE) version 3.0, with the exception of skin-
related and nail-related toxicities, which were graded 
using CTCAE version 3.0 with modiﬁ cations (appendix).
Reasons for stopping a patient from receiving the 
investigational product included: patient withdrawal of 
consent; an administrative decision by the investigator 
or study sponsor; pregnancy; ineligibility; a substantial 
protocol deviation; patient non-compliance; or adverse 
events. If a patient (or a legally acceptable representative) 
requested or decided to withdraw from the study, all 
eﬀ orts were made to complete and report all observations 
as thoroughly as possible up to the date of withdrawal.
In analyses of previous studies of squamous-cell 
carcinoma of the head and neck, HPV status has been 
shown to be both a prognostic factor and a predictor of 
response to cytotoxic chemotherapy.10 As such, HPV data 
were collected from available baseline tumour samples 
before data cutoﬀ  for the primary analysis. All available 
samples were tested for HPV status, irrespective of 
tumour site, because at the time of the study we did not 
know whether HPV-associated cancers could arise from 
nonoropharyngeal sites, such as the oral cavity, 
nasopharynx, or larynx. HPV status of the tumour 
samples was established by an independent, blinded 
central laboratory (Clarient, Aliso Viejo, CA, USA) using 
a validated immunohistochemistry assay (CINtec 
histology kit; Ventana Medical Systems, Tucson, AZ, 
USA) for detection of p16INK4A. Tumour specimens were 
scored as positive, negative, or failed according to a 
prespeciﬁ ed immunohistochemistry scoring guideline. 
Positivity was deﬁ ned as uniform staining in 10% or 
more of tumour cells. Additionally, we did a post-hoc 
exploratory analysis that deﬁ ned positivity as uniform 
staining in 70% or more of tumour cells. We summarise 
eﬃ  cacy results by tumour p16 status.
Central radiation therapy quality assurance was done 
for all patients by the Quality Assurance Review Center 
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(QARC; Lincoln, RI, USA), which was responsible for 
adjudication of radiotherapy planning and protocol 
deviations. Two radiotherapy reviews were required. 
Rapid review required that the treatment plan (including 
planning imaging, dosimetry summaries, descriptions 
of all portals, calculation worksheets, and dose–volume 
histograms) be submitted within 1 week of starting 
treatment. Feedback from the rapid review was returned 
to the treating centre, which implemented corrective 
action, if applicable. Final review occurred within 
1 month of completion of radiotherapy when radiation 
data were submitted. Major deviations of radiotherapy 
included prolongation of treatment for more than 
10 consecutive days, greater than 3% PTV1 receiving 
less than 93% prescribed dose, greater than 25% PTV1 
receiving greater than 110% dose, greater than 10% 
PTV1 receiving greater than 115% dose, or greater than 
1% spinal cord receiving 50 Gy or more. If reviewers 
thought that volumes were drawn inappropriately, 
deviation assignment was based on the corrected 
volumes. A written report of the ﬁ nal review was created 
by QARC.
Outcomes
The primary endpoint of the study was the proportion of 
patients who achieved local-regional control at 2 years 
after randomisation. Local-regional control was deﬁ ned 
as clinical or radiographic absence of disease at the 
primary site and within the radiation ﬁ elds that occurred 
at any time after initiation of treatment and before new 
anticancer therapy (therapeutic neck dissections were 
allowed). Local-regional control failure was deﬁ ned as 
loss of previously achieved local-regional control. To 
achieve local-regional control at 2 years, a patient had to 
achieve local-regional control at some point after 
treatment, with persistent control at 2 years. Patients 
who never achieved local-regional control were thought 
to have persistent disease and local-regional failure from 
the beginning of the study. Patients who achieved local-
regional control earlier and did not have local-regional 
failure until the data cutoﬀ  date were censored at the last 
evaluable disease assessment date before the data cutoﬀ  
date. The proportion of patients who achieved local-
regional control at 2 years was estimated from Kaplan-
Meier analysis.
Secondary eﬃ  cacy endpoints were progression-free 
survival, deﬁ ned as time from ﬁ rst study treatment to any 
recurrence, distant metastasis, or death from any cause; 
overall survival, measured from ﬁ rst study treatment to 
death; duration of local-regional control, deﬁ ned as the 
period from ﬁ rst study treatment until local-regional 
failure or to death from any cause; proportion of patients 
with local-regional control at 6 months and 1 year, deﬁ ned 
as the Kaplan-Meier estimate of the proportion of patients 
with local-regional control at 6 months and 1 year; the 
proportion of patients with a complete response by 
6 months, deﬁ ned using a modiﬁ ed version of the WHO 
criteria during the ﬁ rst 6 months (plus 2 weeks) after 
randomisation; the proportion of patients with an overall 
response by 6 months, deﬁ ned as the incidence of 
Figure 1: Trial proﬁ le
*One patient received only radiotherapy and not panitumumab and was not included in the safety analyses.
180 screened for eligibility
152 patients randomly assigned
62 to chemoradiotherapy
61 received at least one dose of study 
 medication 
90 received at least one dose of study 
 medication* 
1 did not receive any study medication 
39 tumour sample available and 
 HPV testing completed
9 p16-positive 30 p16-negative 15 p16-positive 45 p16-negative
90 to panitumumab plus radiotherapy
28 ineligible
22 tumour sample unavailable 
 for HPV testing
30 tumour sample unavailable 
 for HPV testing
60 tumour sample available and 
 HPV testing completed
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complete response or partial response using a modiﬁ ed 
version of the WHO criteria during the ﬁ rst 6 months 
(plus 2 weeks) after randomisation; persistence of disease; 
and local-regional recurrence of disease.
Secondary safety endpoints were the incidence of early 
death (on or within 30 days after last protocol-speciﬁ ed 
treatment); the proportion of patients who received radio-
therapy, chemotherapy, and panitumumab (if applicable) 
according to the protocol and the timing of planned dose 
delivery; the incidence and severity of prespeciﬁ ed 
protocol-speciﬁ c adverse events; the incidence and severity 
of all other adverse events; substantial changes in 
laboratory values; and the incidence of human anti-
panitumumab antibody formation. We also examined 
exploratory biomarker endpoints.
Statistical analysis
We planned to enrol about 150 patients (60 to receive 
chemoradiotherapy and 90 to receive panitumumab plus 
radiotherapy), assuming that 41% of patients in the 
chemoradiotherapy group would achieve local-regional 
control at 2 years compared with 50% in the 
panitumumab plus radiotherapy group. We did not plan 
any formal hypothesis testing; as a result, all p values are 
descriptive only.
We analysed all eﬃ  cacy endpoints, unless noted 
otherwise, in the eﬃ  cacy analysis set, deﬁ ned as all 
randomly assigned patients who received at least one 
dose of their assigned protocol-speciﬁ c treatment (ie, 
chemotherapy, radiation, or panitumumab)
We did a pre-planned sensitivity analysis on selected 
eﬃ  cacy endpoints in all randomly assigned patients (the 
intention-to-treat analysis set). For this sensitivity 
analysis, we analysed all patients according to what 
treatment they were randomly assigned, irrespective of 
the treatment that they actually received, and the eﬃ  cacy 
endpoints were measured from the randomisation date.
We did a further pre-planned sensitivity analysis on 
selected eﬃ  cacy endpoints (local-regional control at 
2 years, duration of local-regional control, progression-
free survival, and overall survival) to assess the eﬀ ect of 
important protocol deviations using the per-protocol 
analysis set, deﬁ ned as the patients in the eﬃ  cacy 
analysis set without important protocol deviations 
thought to aﬀ ect eﬃ  cacy analyses.
The safety analysis set was deﬁ ned as all randomly 
assigned patients who received at least one dose of 
protocol-speciﬁ ed treatment (ie, chemotherapy, radiation, 
or panitumumab), analysed according to treatment 
received. We estimated the treatment eﬀ ect of 
radiotherapy plus panitumumab compared with 
chemoradiotherapy for all eﬃ  cacy endpoints. Hazard 
ratios (HRs) and 95% CIs were estimated using an 
unstratiﬁ ed Cox proportional hazards model. We used 
the software package SAS 9.2 for the statistical analyses.
This study is registered with ClinicalTrials.gov, number 
NCT00547157.
Chemoradiotherapy 
(n=61)
Panitumumab 
plus radiotherapy 
(n=90)
Sex
Men 55 (90%) 72 (80%)
Women 6 (10%) 18 (20%)
Age (years)
<65 51 (84%) 75 (83%)
≥65 10 (16%) 15 (17%)
Tobacco use
Never 2 (3%) 6 (7%)
Current 28 (46%) 43 (48%)
Former 31 (51%) 41 (46%)
Duration of smoking (years)* 49 71
Median (range) 40 (5–57) 35 (0–61)
Mean (SD) 36·7 (11.3) 33·0 (12.3)
Pack years of tobacco use
≤10 4 (7%) 9 (10%)
>10 45 (74%) 68 (76%)
Missing 12 (20%) 13 (14%)
ECOG performance status†
0 40 (66%) 57 (63%)
1 21 (34%) 31 (34%)
Primary tumour site
Oropharynx 28 (46%) 45 (50%)
Oral cavity 7 (11%) 11 (12%)
Hypopharynx 11 (18%) 13 (14%)
Larynx 15 (25%) 21 (23%)
Radiotherapy delivery modality
IMRT 32 (52%) 49 (54%)
3D-CRT 29 (48%) 41 (46%)
T classiﬁ cation
T1 3 (5%) 7 (8%)
T2 10 (16%) 16 (18%)
T3 26 (43%) 35 (39%)
T4 22 (36%) 32 (36%)
N classiﬁ cation
N0 7 (11%) 11 (12%)
N1 14 (23%) 19 (21%)
N2 37 (61%) 58 (64%)
N3 3 (5%) 2 (2%)
p16
Positive 9 (15%) 15 (17%)
Negative 30 (49%) 45 (50%)
Unassessable 22 (36%) 30 (33%)
p16 unassessable 
oropharynx primary 
tumour site
10 (45%) 15 (50%)
ECOG=Eastern Cooperative Oncology Group. IMRT=intensity-modulated radiation 
therapy. 3D-CRT=three-dimensional conformal radiotherapy. T=tumour. N=node. 
p16=presence of uniform p16INK4A staining in ≥10% of cells. *Data obtained from 
49 current or former smokers in the chemoradiotherapy group and 71 current or 
former smokers in the panitumumab plus radiotherapy group (data missing for 
ten and 13 current or former smokers, respectively). †Two patients in the 
panitumumab plus radiotherapy group had an ECOG performance status of 2.
Table 1: Baseline demographics and disease characteristics 
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Role of the funding source
Amgen funded the trial, and was responsible for data 
collection and the statistical analyses. The trial was 
designed by the funder in collaboration with the study 
steering committee. The funder, study steering 
committee, and coauthors were involved in the 
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Figure 2: Kaplan-Meier 
distribution curves of local-
regional control, 
progression-free survival, 
and overall survival in the 
eﬃ  cacy analysis set
(A) Local-regional control, 
calculated from the ﬁ rst day of 
any study treatment 
(radiotherapy, chemotherapy, 
or panitumumab if applicable) 
to the date of ﬁ rst local-
regional failure or to death due 
to any cause (whichever 
occurred ﬁ rst). Patients who 
did not have regional 
recurrence by the data cutoﬀ  
were censored at last local-
regional control assessment 
date or tumour assessment 
date (if no local-regional 
control assessment had been 
done). (B) Progression-free 
survival, deﬁ ned as time from 
the ﬁ rst day of any study 
treatment to date of ﬁ rst 
disease progression per WHO 
criteria or death; patients not 
meeting these criteria by the 
analysis data cutoﬀ  date had 
their progression-free survival 
time censored at their last 
evaluable disease assessment 
date. (C) Overall survival, 
deﬁ ned as time from the ﬁ rst 
day of study treatment to date 
of death; patients who had 
not died by the analysis data 
cutoﬀ  date were censored at 
their last contact date. 
HR=hazard ratio.
Articles
www.thelancet.com/oncology   Published online January 15, 2015   http://dx.doi.org/10.1016/S1470-2045(14)71200-8 7
interpretation of the data. The funder provided medical 
writing assistance from a third party for this paper. AZ 
and AV had access to all of the raw data. KSO had access 
to the raw biomarker data. The corresponding author 
had full access to all of the data and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
From Nov 30, 2007, to Nov 16, 2009, 152 patients were 
enrolled from 22 sites in eight countries (appendix), 
151 of whom received treatment (ﬁ gure 1). One patient 
was randomly assigned to chemoradiotherapy but was 
found to be ineligible on the same day and removed from 
the study without starting treatment. 61 patients received 
at least one dose of chemoradiotherapy, 89 received at 
least one dose of radiotherapy plus panitumumab, and 
one patient randomly assigned to receive radiotherapy 
plus panitumumab received radiotherapy only and was 
included in the radiotherapy plus panitumumab group 
for eﬃ  cacy analyses and in the chemoradiotherapy group 
for safety analyses.
Baseline demographics and disease characteristics 
were generally balanced between the treatment groups 
(table 1). Years of smoking and pack-years of tobacco use 
were balanced between treatment groups.
Tissue samples for HPV p16 assessment were 
available in 99 (66%) of 151 patients; 24 (24%) tested 
positive for p16 (ie, ≥10% of cells contained p16), and 
75 (76%) were p16-negative (ﬁ gure 1). Either no tissue 
was provided or insuﬃ  cient tissue was available to 
establish p16 status in 52 patients. Baseline demo-
graphics and disease characteristics by p16 are shown 
in the appendix. Patients with p16-positive tumour 
samples were more likely to have oropharyngeal 
tumours, T1–3 tumours, and N2–3 tumours than were 
those with p16-negative tumours. Within each p16 
group, demographics and disease characteristics were 
generally balanced across treatment groups (appendix).
Median follow-up was 123 weeks (IQR 57–157) for 
patients in the chemoradiotherapy group and 107·5 weeks 
(40–147) for those in the radiotherapy plus panitumumab 
group. The data cutoﬀ  for all analyses was Dec 16, 2011.
The proportion of patients who achieved local-regional 
control at 2 years was 61% (95% CI 47–72) in the chemo-
radiotherapy group vs 51% (40–62) in the radiotherapy 
plus panitumumab group. Local-regional failure 
occurred in 23 (38%) of 61 patients in the chemo-
radiotherapy group and 48 (53%) of 90 patients in the 
radiotherapy plus panitumumab group. 14 (23%) of 
61 patients in the chemoradiotherapy group and 27 (30%) 
of 90 patients in the radiotherapy plus panitumumab 
group never achieved local-regional control and thus had 
time to local-regional failure of 0 days. The HR for time 
to local-regional failure was 1·61 (95% CI 0·98–2·66; 
p=0·06; ﬁ gure 2A).
Progression-free survival at 2 years in patients receiving 
chemoradiotherapy was 62% (95% CI 49–73) versus 
41% (31–52) in patients receiving radiotherapy plus 
panitumumab. Progression-free survival events (local, 
regional, or distant progression or death) occurred in 
24 (39%) of 61 patients in the chemoradiotherapy group, 
and in 53 (59%) of 90 patients in the radiotherapy plus 
panitumumab group (HR 1·73, 95% CI 1·07–2·81; 
p=0·03; ﬁ gure 2B).
Overall survival at 2 years in patients receiving 
chemoradiotherapy was 71% (95% CI 58–81) versus 
63% (51–72) in patients receiving radiotherapy plus 
panitumumab. 18 (30%) of 61 patients in the 
chemoradiotherapy group and 38 (42%) of 90 patients in 
the radiotherapy plus panitumumab group died during 
the study (HR 1·59, 95% CI 0·91–2·79; p=0·10; 
ﬁ gure 2C).
In the 24 patients with p16-positive tumours, 
67% (95% CI 28–88) had local-regional control at 2 years 
in the chemoradiotherapy group compared with 
66% (36–84) in the radiotherapy plus panitumumab 
group (HR 0·95, 95% CI 0·22–4·01; p=0·94); 
progression-free survival at 2 years in these patients was 
Overall (n=151)  1·73 (1·07–2·81) 0·03
p16+ (n=24)  1·22 (0·30–4·86) 0·78
p16– (n=75)  2·04 (1·05–3·96) 0·04
Unknown (n=52)  1·52 (0·66–3·47) 0·32
Overall (n=151)  1·59 (0·91–2·79) 0·10
p16+ (n=24)  2·80 (0·31–25·07) 0·36
p16– (n=75)  1·93 (0·90–4·16) 0·09
Unknown (n=52)  1·04 (0·41–2·65) 0·93
Overall n=151)  1·73 (1·07–2·81) 0·03
p16+ (n=18)  1·48 (0·35–6·26) 0·59
p16– (n=81)  1·90 (0·98–3·69) 0·06
Unknown (n=52)  1·52 (0·66–3·47) 0·32
Overall (n=151)  1·59 (0·91–2·79) 0·10
p16+ (n=18)  2·86 (0·30–27·61) 0·36
p16– (n=81)  1·87 (0·87–4·01) 0·11
Unknown (n=52)  1·04 (0·41–2·65) 0·93
0·01 0·1 1 10 100
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Figure 3: Forest plots of progression-free and overall survival according to HPV status, measured by extent of 
p16 positivity in tumour sample
Progression-free and overall survival according to p16 positivity when deﬁ ned as uniform staining in 10% or more 
of tumour cells (A) and when deﬁ ned as uniform staining in 70% or more of tumour cells (B). 
CRT=chemoradiotherapy. HPV=human papillomavirus. HR=hazard ratio. PaRT=radiotherapy plus panitumumab.
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76% (95% CI 33–94) in the chemoradiotherapy group 
versus 60% (32–80) in the radiotherapy plus 
panitumumab group, and overall survival at 2 years was 
89% (43–98) in the chemoradiotherapy group versus 73% 
(44–89) in the radiotherapy plus panitumumab group 
(ﬁ gure 3A).
In the 75 patients with p16-negative tumours, 
61% (41–76) had local-regional control at 2 years in the 
chemoradiotherapy group versus 45% (29–59) in the 
radiotherapy plus panitumumab group (HR 1·90, 
95% CI 0·94–3·81; p=0·07); progression-free survival at 
2 years was 62% (95% CI 42–77) in the chemoradiotherapy 
group versus 33% (20–47) in the radiotherapy plus 
panitumumab group, and overall survival at 2 years was 
73% (95% CI 53–85) in the chemoradiotherapy group 
versus 55% (40–68) in the radiotherapy plus 
panitumumab group (HR 1·93, 0·90–4·16; p=0·09; 
ﬁ gure 3A).
In an exploratory analysis using the alternative cutoﬀ  
of 70% or greater cells with p16 to deﬁ ne HPV positivity, 
six patients who had p16-positive tumours were 
reclassiﬁ ed as having p16-negative tumours; progression-
free and overall survival subgroup analysis for all patients 
using this cutoﬀ  is shown in ﬁ gure 3B.
Grade 1 or 2 adverse events occurring in at least 10% of 
patients in one treatment group are shown in table 2, and 
all grade 3 and 4 adverse events are shown in table 3. 
Adverse events were generally balanced between 
treatment groups, with the exception of skin toxicity 
(both associated and not associated with radiation), 
which was more common in the radiotherapy plus 
panitumumab group, and neutropenia and febrile 
neutropenia, which were more common in the chemo-
radiotherapy group. Common grade 3 or worse adverse 
events were mucosal inﬂ ammation (at least one event 
was reported in 25 [40%] of 62 patients in the 
chemoradiotherapy group vs 37 [42%] of 89 patients in 
the radiotherapy plus panitumumab) and dysphagia 
(20 [32%] of 62 vs 36 [40%] of 89). Treatment-related 
adverse events (data not shown) leading to permanent 
discontinuation of study drug or removal from study 
were reported in two (3%) of 62 patients in the 
chemoradiotherapy group and in ten (11%) of 89 patients 
in the radiotherapy plus panitumumab group. Serious 
adverse events were reported in 25 (40%) of 62 patients 
in the chemoradiotherapy group and in 30 (34%) of 
89 patients in the radiotherapy plus panitumumab group 
(appendix). Two (3%) deaths due to adverse events were 
reported in the chemoradiotherapy group (one case of 
pneumonia and one cardiorespiratory arrest) versus ﬁ ve 
(6%) in the radiotherapy plus panitumumab group (two 
sudden deaths, one case of pneumonia, one death not 
otherwise speciﬁ ed, and one case of septic shock). All but 
the two sudden deaths in the radiotherapy plus 
panitumumab group were considered unrelated to study 
treatment.
Median relative dose intensity was 99% 
(IQR 93·5–100·6) for cisplatin in patients receiving 
chemo radiotherapy and 100% (95·5–102) for 
panitumumab in patients receiving radiotherapy plus 
panitumumab. Median total dose of radiotherapy was 
72 Gy (IQR 70–72) in patients receiving chemo-
radiotherapy and those receiving radiotherapy plus 
panitumumab. No major radiotherapy deviations 
occurred in either group of the study. In the radiotherapy 
plus panitumumab group, six (7%) of 90 patients had 
treatment interruptions that lasted for more than 
10 cumulative days compared with none in the 
chemoradiotherapy group. The median chemotherapy 
dose delay was 4·0 days (range 1–10) in seven patients in 
the chemoradiotherapy group. Cisplatin dose changes 
were reported in 20 (32%) of 62 patients receiving 
chemoradiotherapy. Median duration of radiotherapy 
dose interruptions was 2·0 days (IQR 1·0–4·0) for the 
chemoradiotherapy group and 2·0 days (2·0–5·5) for 
radiotherapy plus panitumumab group. The median 
panitumumab dose delay was 3·0 days (range 1–16) for 
Chemoradiotherapy 
(n=62)
Panitumumab plus 
radiotherapy (n=89)
Grade 1 Grade 2 Grade 1 Grade 2
Rash 1 (2%) 1 (2%) 40 (45%) 34 (38%)
Mucosal inﬂ ammation 25 (40%) 34 (55%) 32 (36%) 46 (52%)
Radiation skin injury 26 (42%) 19 (31%) 31 (35%) 34 (38%)
Dry mouth 17 (27%) 7 (11%) 24 (27%) 12 (13%)
Dysphagia 19 (31%) 27 (44%) 23 (26%) 45 (51%)
Constipation 12 (19%) 3 (5%) 22 (25%) 9 (10%)
Odynophagia 9 (15%) 16 (26%) 20 (22%) 20 (22%)
Weight decreased 14 (23%) 10 (16%) 18 (20%) 17 (19%)
Nausea 22 (35%) 10 (16%) 15 (17%) 5 (6%)
Stomatitis 8 (13%) 8 (13%) 15 (17%) 18 (20%)
Dysgeusia 14 (23%) 8 (13%) 14 (16%) 7 (8%)
Dysphonia 2 (3%) 3 (5%) 13 (15%) 4 (4%)
Fatigue 9 (15%) 1 (2%) 13 (15%) 6 (7%)
Dermatitis 6 (10%) 8 (13%) 12 (13%) 14 (16%)
Asthenia 10 (16%) 7 (11%) 11 (12%) 3 (3%)
Erythema 4 (6%) 0 11 (12%) 4 (4%)
Pruritus 0 0 11 (12%) 4 (4%)
Acne 0 0 9 (10%) 4 (4%)
Cough 5 (8%) 1 (2%) 9 (10%) 1 (1%)
Dermatitis acneiform 0 0 9 (10%) 12 (13%)
Pyrexia 8 (13%) 1 (2%) 9 (10%) 0
Vomiting 9 (15%) 9 (15%) 9 (10%) 8 (9%)
Decreased appetite 10 (16%) 2 (3%) 7 (8%) 5 (6%)
Diarrhoea 7 (11%) 0 4 (4%) 3 (3%)
Hypokalaemia 7 (11%) 0 4 (4%) 0
Ageusia 1 (2%) 5 (8%) 1 (1%) 10 (11%)
Oral candidiasis 2 (3%) 9 (15%) 6 (7%) 6 (7%)
Data are number of patients with at least one event (% of patients).
Table 2: Grade 1 and 2 adverse events occurring in at least 10% of 
patients in one or both treatment groups
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Chemoradiotherapy 
(n=62)
Panitumumab plus 
chemoradiotherapy 
(n=89)
Grade 3 Grade 4 Grade 3 Grade 4
Dysphagia 19 (31%) 1 (2%) 34 (38%) 2 (2%)
Mucosal inﬂ ammation 25 (40%) 0 33 (37%) 4 (4%)
Radiation skin injury 6 (10%) 1 (2%) 20 (22%) 1 (1%)
Stomatitis 3 (5%) 0 13 (15%) 1 (1%)
Dermatitis 0 0 12 (13%) 3 (3%)
Rash 0 0 8 (9%) 0
Odynophagia 12 (19%) 0 7 (8%) 0
Radiation mucositis 1 (2%) 0 6 (7%) 0
Pain 4 (6%) 0 5 (6%) 0
Decreased appetite 4 (6%) 0 4 (4%) 0
Pharyngitis 2 (3%) 0 4 (4%) 0
Acne 0 0 2 (2%) 0
Anaemia 2 (3%) 0 2 (2%) 0
Aphonia 0 0 2 (2%) 0
Confusional state 0 0 2 (2%) 0
Dehydration 4 (6%) 0 2 (2%) 1 (1%)
Dermatitis acneiform 0 0 2 (2%) 0
Hypokalaemia 3 (5%) 1 (2%) 2 (2%) 0
Skin infection 0 0 2 (2%) 0
Skin reaction 0 0 2 (2%) 0
Agitation 0 0 1 (1%) 0
Benign prostatic 
hyperplasia
0 0 1 (1%) 0
Candidiasis 0 0 1 (1%) 0
Deep-vein thrombosis 0 0 1 (1%) 0
Delirium 0 0 1 (1%) 0
Diarrhoea 0 0 1 (1%) 0
Dyspnoea 1 (2%) 1 (2%) 1 (1%) 2 (2%)
Erythema 1 (2%) 0 1 (1%) 0
Facial pain 0 0 1 (1%) 0
Gastric perforation 0 0 1 (1%) 0
Glossodynia 0 0 1 (1%) 0
Headache 0 0 1 (1%) 0
Herpes zoster 0 0 1 (1%) 0
Hyperbilirubinaemia 0 0 1 (1%) 1 (1%)
Hypertension 0 0 1 (1%) 0
Hypoglycaemia 0 0 1 (1%) 0
Hyponatraemia 3 (5%) 0 1 (1%) 0
Infection 1 (2%) 0 1 (1%) 0
Leukocytoclastic vasculitis 0 0 1 (1%) 0
Lower respiratory tract 
infection
0 0 1 (1%) 0
Nausea 1 (2%) 0 1 (1%) 0
Neck pain 1 (2%) 0 1 (1%) 0
Neuralgia 0 0 1 (1%) 0
Oesophagitis 0 0 1 (1%) 0
Oral pain 1 (2%) 0 1 (1%) 0
Oropharyngeal pain 2 (3%) 0 1 (1%) 0
Pain in jaw 0 0 1 (1%) 0
(Table 3 continues in next column)
Chemoradiotherapy 
(n=62)
Panitumumab plus 
chemoradiotherapy 
(n=89)
Grade 3 Grade 4 Grade 3 Grade 4
(Continued from previous column)
Post-procedural 
haemorrhage
0 0 1 (1%) 0
Pruritus 0 0 1 (1%) 0
Pyrexia 0 0 1 (1%) 0
Radiation injury 1 (2%) 0 1 (1%) 0
Renal failure 0 0 1 (1%) 0
Respiratory failure 0 0 1 (1%) 0
Respiratory-tract infection 1 (2%) 0 1 (1%) 0
Rosacea 0 0 1 (1%) 0
Staphylococcal infection 0 0 1 (1%) 0
Stridor 0 0 1 (1%) 0
Swelling face 0 0 1 (1%) 0
Syncope 2 (3%) 0 1 (1%) 0
Toxicity to various agents 1 (2%) 0 1 (1%) 0
Tumour pain 0 0 1 (1%) 0
Urticaria 0 0 1 (1%) 0
Weight decreased 1 (2%) 0 1 (1%) 0
Anxiety 1 (2%) 0 0 0
Aphagia 1 (2%) 0 0 0
Asthenia 3 (5%) 0 0 0
Drug eruption 1 (2%) 0 0 0
Dry mouth 1 (2%) 0 0 0
Dysphonia 2 (3%) 0 0 0
Febrile neutropenia 3 (5%) 2 (3%) 0 0
Feeding tube complication 1 (2%) 0 0 0
Hypoalbuminaemia 2 (3%) 0 0 0
Left ventricular 
dysfunction
1 (2%) 0 0 0
Leucopenia 3 (5%) 0 0 0
Neutropenia 8 (13%) 2 (3%) 0 0
Oropharyngitis fungal 1 (2%) 0 0 0
Pharyngeal inﬂ ammation 1 (2%) 0 0 0
Pulmonary hypertension 1 (2%) 0 0 0
Thrombocytopenia 2 (3%) 1 (2%) 0 0
Tooth abscess 1 (2%) 0 0 0
Vomiting 1 (2%) 0 0 0
Alcohol poisoning 0 0 0 1 (1%)
Endocarditis 0 0 0 1 (1%)
Pneumonia 0 1 (2%) 0 1 (1%)
Septic shock 0 0 0 1 (1%)
Myocardial infarction 0 1 (2%) 0 0
Oedema 0 1 (2%) 0 0
Sudden death 0 0 0 0
Death 0 0 0 0
Cardiorespiratory arrest 0 0 0 0
Data are number of patients with at least one event (% of patients). Two (3%) 
deaths due to adverse events were reported in the chemoradiotherapy group (one 
case of pneumonia and one cardiorespiratory arrest) versus ﬁ ve (6%) in the 
radiotherapy plus panitumumab group (two sudden deaths, one case of 
pneumonia, one death not otherwise speciﬁ ed, and one case of septic shock).
Table 3: All grade 3 and 4 adverse events
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the radiotherapy plus panitumumab group. One 
panitumumab dose change was recorded in 29 (33%) of 
89 patients, two panitumumab dose changes were 
recorded in ten (11%) of 89 patients receiving 
panitumumab, and three panitumumab dose changes 
were recorded in one (1%) of 89 patients receiving 
panitumumab. Nodal surgery was done in 14 (23%) of 
62 patients receiving chemo radio therapy and in 13 (14%) 
of 90 patients receiving radiotherapy plus panitumumab. 
Most patients had unilateral node dissection (12 [86%] of 
14 in the chemoradiotherapy group vs ten [77%] of 13 in 
the radiotherapy plus panitumumab group) and complete 
resection (12 [86%] vs 12 [92%] of 13).
Discussion
In this study of patients with locally advanced squamous-
cell carcinoma of the head and neck, the proportion of 
patients achieving 2-year local-regional control was 
61% (47–72) for in the chemoradiotherapy group and 
51% (40–62) in the radiotherapy plus panitumumab 
group. The HR for progression-free survival was 
1·73 (95% CI 1·07–2·81; p=0·03) and for overall survival 
was 1·59 (0·91–2·79; p=0·10). Thus we conclude that, in 
unresected stage III–IVb squamous-cell carcinoma of 
the head and neck, panitumumab cannot replace 
cisplatin in combined treatment with radiotherapy, and 
these results call into question the role of EGFR 
inhibitors in this setting.
Cisplatin-based chemoradiotherapy is the standard of 
care for the treatment of locally advanced squamous-cell 
carcinoma of the head and neck.4,11,12 To our knowledge, 
our study is the ﬁ rst that directly estimates the eﬀ ect of 
chemoradiotherapy versus radiotherapy combined with 
an anti-EGFR agent. In this randomised phase 2 trial, we 
noted that the two regimens have toxicity proﬁ les similar 
to those seen historically with chemoradiotherapy and 
EGFR inhibitors.2,13 Outcomes seemed to favour the 
chemoradiotherapy group in all eﬃ  cacy endpoints, 
irrespective of p16 status.
This study was a phase 2 estimation trial with a sample 
size that was not powered to do any formal hypothesis 
testing. The trial was designed to estimate the treatment 
eﬀ ect in this population, and if the results were positive, 
would have led to the development of a phase 3 trial with 
a sample size adequately powered for formal hypothesis 
testing.
The results from the radiotherapy plus panitumumab 
group are very similar to the results from the radiotherapy 
plus cetuximab group in Bonner and colleagues’ trial,2 
with 51% of patients achieving local-regional control at 
2 years in our study compared with 50% in Bonner and 
colleagues’ study, with a median survival of 42 months 
and 49 months, respectively. Prognostic factors in the 
two studies were similar. In our study, 45 (50%) of 
90 patients in the radiotherapy plus panitumumab group 
had oropharyngeal tumours compared with 56% of 
patients in the radiotherapy plus cetuximab group in 
Bonner and colleagues’ study. The results obtained in 
our chemoradiotherapy group were also consistent with 
results from other recent trials.5,6 Progression-free and 
overall survival at 2 years in the chemoradiotherapy 
group were 62% and 73%, respectively, in our study, 65% 
and 80%, respectively, in CONCERT-1,6 and 64% and 
80%, respectively in RTOG 0522.5 Overall, the survival 
results from these three trials are better than those 
reported by other phase 3 trials of chemoradiotherapy 
reported previously.13–15
Increased experience and more widespread use of 
cisplatin plus radiation are likely to have improved 
outcomes during the past decade, which is possibly 
attributable to improved staging of patients, toxicity 
management strategies, and radiation techniques. 
Diﬀ erences reported between chemoradiotherapy and 
radiotherapy plus panitumumab might be explained by 
the toxicity proﬁ le. More toxic deaths occurred in the 
radiotherapy plus panitumumab group (6% vs 3%), as 
more did radiotherapy interruptions lasting longer than 
10 days (7% vs 0%), and more permanent discontinuations 
of study (16% vs 5%), although these results are probably 
partly due to patients in the radiotherapy plus 
panitumumab group being given panitumumab for 
longer (three cycles) than those given cisplatin in the 
chemoradiotherapy group (two cycles). EGFR inhibitor-
associated skin toxicity probably also contributed to 
higher incidences of radiation-related skin toxicity in this 
trial. Another possible cause of increased toxicities is the 
panitumumab schedule. Panitumumab 9·0 mg/kg every 
3 weeks was thought to be an equivalent dose to weekly 
2·5 mg/kg; however, these schedules have never been 
compared in combination with radiotherapy.16
Only 50% of our patients had oropharyngeal tumours 
and, of all patients, the incidence of patients with p16-
positive tumours (deﬁ ned using the 10% cutoﬀ ) was 
16%. We believe that the eﬀ ect of HPV in our study was 
very low and outcomes favouring chemoradiotherapy 
were largely driven by patients with p16-negative 
tumours. Whether substitution of a platinum-based 
chemotherapy with an anti-EGFR agent in patients with 
p16-positive tumours will be useful is unclear. The 
National Cancer Institute of Canada’s Clinical Trials 
Group is comparing panitumumab with chemotherapy 
in the setting of radiotherapy in 320 patients 
(NCT00820248). This trial should be completed in 2015 
and might provide additional information on the role of 
panitumumab versus chemotherapy in patients with and 
without HPV. The Radiation Therapy Oncology Group 
(RTOG) is also doing a trial of cetuximab plus 
radiotherapy versus chemoradiotherapy in HPV-positive, 
locally advanced oropharyngeal cancer (NCT01302834).
The TREMPLIN trial,17 a randomised, phase 2 study for 
larynx preservation, compared cetuximab plus radio-
therapy with cisplatin plus radiotherapy after induction 
chemotherapy. No diﬀ erence in local-regional failure was 
seen between groups, although patients enrolled in this 
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trial received induction chemotherapy, and only patients 
who responded were eligible for randomisation. The 
trend towards an increased proportion of patients who 
had local-regional failure in the radiotherapy plus 
panitumumab group in our study was similar to that 
reported in patients assigned to cetuximab in TREMPLIN. 
Although we recognise that the two studies have their 
diﬀ erences, the results reported in TREMPLIN are 
consistent with those reported in CONCERT-2.
We used accelerated concomitant boost radiotherapy in 
both groups of this study. In Bonner and colleagues’ 
study,3 a forest plot analysis showed that patients who 
received a concomitant boost had an increased likelihood 
of improved survival. The RTOG 0129 trial10 compared 
two cycles of concomitant chemotherapy plus 72 Gy 
radiotherapy in 6 weeks with three cycles of cisplatin 
chemotherapy plus conventional 70 Gy radiotherapy in 
7 weeks. No safety or eﬃ  cacy beneﬁ t was reported with 
the 1 week acceleration of radiotherapy, so the usefulness 
of accelerated-dose radiotherapy, though frequently used, 
is uncertain. The GORTEC 99-02 study15 recently 
conﬁ rmed these trends and conclusions.
In summary, CONCERT-2 showed higher 2-year local-
regional control and progression-free survival in patients 
who received chemoradiotherapy than in those who 
received radiotherapy plus panitumumab for unresected, 
stage III–IVb, predominantly p16-negative, squamous-
cell carcinoma of the head and neck, leading to the 
conclusion that panitumumab in combination with 
radiotherapy cannot replace cisplatin plus radiotherapy 
in these patients. Furthermore, the addition of 
panitumumab to chemoradiotherapy does not confer any 
beneﬁ t and seems to increase toxicity.6 As such, the use 
of targeted therapies needs to be reassessed in locally 
advanced squamous-cell carcinoma of the head and neck. 
Although opportunities to improve the therapeutic ratio 
in some patients with squamous-cell carcinoma of the 
head and neck might still exist, further research is 
necessary to investigate in which, if any, subset of 
patients the use of EGFR inhibitors could be of clinical 
beneﬁ t.
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